Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes

No studies evaluated the role of F8 mutations in outcomes for low‐dose immune tolerance induction (ITI) in people with severe hemophilia A (SHA) with high‐titer inhibitors.

[1]  M. Margaglione,et al.  Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  Guoqing Liu,et al.  Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors , 2021, Research and practice in thrombosis and haemostasis.

[3]  Guoqing Liu,et al.  A low‐dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high‐titre factor VIII inhibitor and poor‐ITI prognostic risk , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Shapiro,et al.  Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. , 2019, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  C. Königs,et al.  Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A. , 2019, Blood.

[6]  F. Peyvandi,et al.  Risk factors for inhibitor development in severe hemophilia a. , 2018, Thrombosis research.

[7]  S. Ohga,et al.  The Japanese Immune Tolerance Induction (J‐ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  V. Ramanan,et al.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.

[9]  M. Lyle,et al.  Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. , 2016, Cellular immunology.

[10]  S. Donfield,et al.  Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two US centres , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[12]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[14]  M. Margaglione,et al.  Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high‐responding inhibitors , 2009, Journal of thrombosis and haemostasis : JTH.

[15]  D. DiMichele.  The North American Immune Tolerance Registry: contributions to the thirty‐year experience with immune tolerance therapy , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  E. Santagostino,et al.  Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice , 2008, Journal of thrombosis and haemostasis : JTH.

[17]  G. Castaman,et al.  F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  P. Mannucci,et al.  Genetic diagnosis of haemophilia and other inherited bleeding disorders , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  E. Santagostino,et al.  Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. , 2006, Haematologica.

[20]  J. Katz,et al.  The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.

[21]  J. Batlle,et al.  Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  G. Mariani,et al.  Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. , 2001, Haematologica.